Dec. 13, 2007 Results of Eastern Cooperative Oncology Group Phase III clinical trial E4A03, for multiple myeloma, showing significantly better overall survival with lenalidomide plus low-dose dexamethasone therapy compared to lenalidomide plus high-dose dexamethasone, were reported December 10 by S. Vincent Rajkumar, M.D. at the American Society of Hematology's annual meeting.
Currently lenalidomide and high-dose dexamethasone, referred to as Rev/Dex, is used as second-line treatment for myeloma. This same treatment has been used off-label (not currently approved by the U.S. Food and Drug Administration (FDA) for this particular use) by physicians for their newly-diagnosed patients, with overall response rates and one-year survival rates in the 90 percent range.
"The standard treatment for myeloma usually includes high doses of steroids such as dexamethasone. In this study we were hoping to find that a lower dose of steroids would be just as effective," says Dr. Rajkumar, Mayo Clinic Cancer Center hematologist and lead investigator of the study. "We were surprised to find that the regimen with high-dose steroids actually was decreasing survival, besides contributing to increased side effects."
The study compared combination treatment of oral medications lenalidomide (a novel chemotherapeutic agent) and either high- or low-dose dexamethasone (a potent steroid effective against myeloma) in 445 patients with newly diagnosed myeloma. Lenalidomide plus high-dose dexamethasone had an 18-month survival rate of 80 percent. The comparative therapy using low-dose dexamethasone showed a significantly higher 91 percent overall survival rate at 18 months, with much less toxicity.
"The lower survival rates with the high-dose dexamethasone can be attributed to disease progression as well as treatment-related toxicities," says Dr. Rajkumar. "This is a major advance in the treatment of this cancer, and also gives researchers a new direction to explore -- that more is not necessarily better."
All patients on the high-dose dexamethasone arm of the clinical trial were moved to the low-dose arm in April 2007, following an early closure announcement.
Mayo Clinic's Rafael Fonseca, M.D., and Philip Greipp, M.D., assisted in the research. Other researchers contributing to the study included Susanna Jacobus, Dana Farber Cancer Institute, Boston; Natalie Callander, M.D., University of Wisconsin, Madison; David Vesole, M.D., Ph.D., St. Vincent's Hospital, New York; Michael Williams, M.D., University of Virginia, Charlottesville; Rafat Abonour, M.D., Indiana University, Indianapolis; and David Siegel, M.D., Ph.D.; Hackensack University Medical Center, New Jersey.
Multiple myeloma, also called myeloma, is an incurable plasma cell (white blood cells in bone marrow) cancer, for which the cause is unknown. The American Cancer Society reports that nearly 20,000 people will have been diagnosed with myeloma by the end of 2007. Myeloma interferes with bone marrow function and the immune system, and can cause bones to erode, anemia, infection and possibly kidney failure.
Other social bookmarking and sharing tools:
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Note: If no author is given, the source is cited instead.